Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bacillus Calmette-Guerin + interferon alpha-2b
- Development stage
- Unknown
- Lead developer
- National University Hospital
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intravesical
01
Overview
This is an investigational combination immunotherapy regimen consisting of Bacillus Calmette-Guerin (BCG) and interferon alpha-2b, specifically evaluated by the National University Hospital, Singapore, for the treatment of high-risk superficial (non-muscle invasive) bladder cancer. BCG is a live attenuated strain of Mycobacterium bovis that, when administered intravesically, induces a robust local inflammatory and immune response characterized by the activation of macrophages, T-cells, and the production of various cytokines. Interferon alpha-2b is a recombinant cytokine that further modulates the immune system, enhancing the anti-tumor activity and potentially allowing for a reduction in the BCG dose to mitigate toxicity. Clinical trials conducted by the National University Hospital have demonstrated that this combination therapy provides superior recurrence-free survival and significantly lower local and systemic toxicity compared to standard-dose BCG monotherapy in patients with aggressive superficial bladder cancer.
- Other names
- BCG + interferon alpha-2bBCG and interferon alphalow dose BCG + interferon alpha-2bBacillus Calmette-Guerin and interferon alpha-2b
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)TLR2 (Toll-like Receptor 2)IFNAR (Immune system modulation via type I interferon receptor)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Bacillus Calmette-Guerin + interferon alpha-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bacillus Calmette-Guerin + interferon alpha-2b.